| Identification | Back Directory | [Name]
2H-Indol-2-one, 1,3-dihydro-3-(2-pyridinylmethylene)-, (3Z)- | [CAS]
187325-53-7 | [Synonyms]
GSK-3β inhibitor 1
2H-Indol-2-one, 1,3-dihydro-3-(2-pyridinylmethylene)-, (3Z)- | [Molecular Formula]
C14H10N2O | [MDL Number]
MFCD00435358 | [MOL File]
187325-53-7.mol | [Molecular Weight]
222.24 |
| Chemical Properties | Back Directory | [Boiling point ]
457.2±45.0 °C(Predicted) | [density ]
1.291±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.34±0.20(Predicted) | [color ]
Yellow to orange | [InChI]
InChI=1S/C14H10N2O/c17-14-12(9-10-5-3-4-8-15-10)11-6-1-2-7-13(11)16-14/h1-9H,(H,16,17)/b12-9- | [InChIKey]
YKQONSWBHGBDSB-XFXZXTDPSA-N | [SMILES]
N1C2=C(C=CC=C2)/C(=C/C2=NC=CC=C2)/C1=O |
| Hazard Information | Back Directory | [Uses]
GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats[1]. | [in vivo]
GSK-3β inhibitor 1 (50 mg/kg, i.p., 30 min prior to glucose challenge) effectively prevents increase in blood glucose levels in HFD+STZ diabetic rats[1].
| Animal Model: | HFD+STZ diabetic rats [1] . | | Dosage: | 50 mg/kg | | Administration: | i.p., 30 min prior to glucose challenge | | Result: | Vehicle-treated diabetic rats developed persistent hyperglycemic response. Administration of GSK-3β inhibitor 1 30 min prior to glucose challenge effectively prevented increase in blood glucose levels.
|
| [IC 50]
GSK-3β: 4.9 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Lozinskaya NA, et al. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors. Bioorg Med Chem. 2019 May 1;27(9):1804-1817. DOI:10.1016/j.bmc.2019.03.028 |
|
|